Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Orion Oyj

Orion Corporation focuses on developing and manufacturing pharmaceutical products and self-described well-being solutions, including medicines and therapies in areas such as pain, cancer, and respiratory diseases.

Metric
Company Name	Orion Oyj
Symbol	ORNAV
MSH ID	FI:ORION
Market	STOCKS
Sector	Healthcare
Industry	Drug Manufacturers - General
Country	FI
Stage
Employee Count	3.70K
Website	orion.fi
LinkedIn
Founders

Metric
Market Cap	6.09B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	1.26B
Revenue (LTM)
Revenue (NTM)
Gross Profit	694.79M
EBITDA	298.70M
Operating Income	244.31M
Net Income	228.99M
EPS	1.64
Diluted EPS	1.63
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.56
Operating Profit Margin	0.20
EBITDA Margin	0.24
Net Profit Margin	0.18
Return on Equity	0.29
Return on Assets	0.16
Return on Capital Employed	0.24

FI:ORION

Orion Corporation

Last Close

44.90

25/11 09:33

Market Cap

5.77B

Beta: -

Volume Today

431

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	33.96
P/B Ratio	7.00
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.49
EV Multiple	23.35

Metric
Days Sales Outstanding
Days Payables Outstanding	56.73
Days Inventory Outstanding	254.79
Operating Cycle	357.92
Cash Conversion Cycle	291.56
Asset Turnover	0.86

Metric
Operating Cash Flow	125.69M
Free Cash Flow	2.32M
Cash Flow to Debt	1.16
Operating Cash Flow/Sales	0.18
Free Cash Flow Yield	-0.01

Metric
Cash & Equivalents	112.70M
Accounts Receivable	-94.00M
Inventory	382.57M
Goodwill	92.10M
Debt to Capitalization	0.26
Debt to Assets	0.15
Current Ratio	3.10
Quick Ratio	1.75

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.11
SG&A to Revenue	0.06